Ganciclovir phrophylaxis delays but does not prevent cytomegalovirus infection in renal transplant recipients

A. Israni, K. Krok, D. Cohen, E. Blumberg, Roy D. Bloom

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Cytomegalovirus (CMV) infection is associated with reduced graft and patient survival among renal transplant recipients. The purpose of this study was to examine the effect of routine prophylaxis with 12 weeks of oral ganciclovir on the incidence of CMV infection in a center that predominantly uses antibody induction together with tacrolimus/mycophenolate mofetil-based maintenance immunosuppressive therapy. The control group consisted of a historical patient cohort transplanted immediately prior to the use of oral ganciclovir prophylaxis. The use of tacrolimus (88% vs 77%, P = .02) and cytolytic therapy (81% vs 46%, P < .0001) was likewise greater among patients who received ganciclovir prophylaxis. CMV infection occurred in 20 (9%) patients in the ganciclovir era and 4 (3%) patients in the preganciclovir era (P = .003). The mean time to CMV infection was longer in patients who received ganciclovir prophylaxis than in patients in the preganciclovir era (23.4 ± 10.9 weeks vs 9.8 ± 5.6 weeks, P = .03). We conclude that 12 weeks of ganciclovir prophylaxis delays but does not prevent CMV infection from occurring in renal transplant recipients. These results suggest that with the use of 12 weeks of ganciclovir prophylaxis, vigilance for CMV infection is needed well beyond 24 weeks posttransplant.

Original languageEnglish (US)
Pages (from-to)3019-3024
Number of pages6
JournalTransplantation proceedings
Issue number10
StatePublished - 2004

All Science Journal Classification (ASJC) codes

  • Surgery
  • Transplantation


Dive into the research topics of 'Ganciclovir phrophylaxis delays but does not prevent cytomegalovirus infection in renal transplant recipients'. Together they form a unique fingerprint.

Cite this